Search

Rainer Ziermann Phones & Addresses

  • San Diego, CA
  • Santa Clara, CA
  • Sunnyvale, CA
  • 60 Corte Yolanda, Moraga, CA 94556 (925) 284-4104
  • 3908 Leona St, San Mateo, CA 94403 (650) 525-9723
  • San Francisco, CA
  • Orinda, CA
  • El Cerrito, CA
  • Berkeley, CA
  • Lafayette, CA
  • 3062 Millar Ave, Santa Clara, CA 95051

Work

Company: Talis biomedical corporation Jan 2018 Position: Vice president medical and scientific affairs

Education

School / High School: University of California, San Francisco 1994 to 1996 Specialities: Virology

Skills

Clinical Trials • Clinical Research and Development • Cross Functional Team Leadership • Infectious Diseases • Virology • Strategic Planning • Biotechnology • Medical Devices • Scientific Affairs • Research and Development • Pre Submissions

Languages

German • English

Industries

Biotechnology

Resumes

Resumes

Rainer Ziermann Photo 1

Vice President Medical And Scientific Affairs

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Talis Biomedical Corporation
Vice President Medical and Scientific Affairs

Hologic (Formerly Gen-Probe) Oct 2015 - Jun 2017
Vice President Clinical Affairs

Ibis Biosciences/Abbott Sep 2013 - Oct 2015
Senior Director Clinical and Regulatory Affairs

Cepheid May 2010 - Sep 2013
Vice President Clinical Affairs

Roche Dec 2007 - Apr 2010
Senior Director Clinical Research
Education:
University of California, San Francisco 1994 - 1996
University of California, Berkeley 1990 - 1994
Doctorates, Doctor of Philosophy, Molecular Biology, Philosophy
Ludwig - Maximilians Universität München 1986 - 1990
Masters, Genetics
University of Bayreuth 1984 - 1986
Skills:
Clinical Trials
Clinical Research and Development
Cross Functional Team Leadership
Infectious Diseases
Virology
Strategic Planning
Biotechnology
Medical Devices
Scientific Affairs
Research and Development
Pre Submissions
Languages:
German
English

Publications

Us Patents

14-Methyl Epothilone Derivatives

View page
US Patent:
6583290, Jun 24, 2003
Filed:
Nov 28, 2000
Appl. No.:
09/724882
Inventors:
Bryan Julien - Oakland CA
Leonard Katz - Hayward CA
Chaitan Khosla - Palo Alto CA
Li Tang - Foster City CA
Rainer Ziermann - San Mateo CA
Assignee:
Kosam Biosciences, Inc. - Hayward CA
International Classification:
C07D27722
US Classification:
548203, 181205, 5462681
Abstract:
Compounds of the invention include 14-mehtyl epothilone derivatives. More generally, preferred compounds of the invention are those that can be produced by altering the epothilone PKS genes as described herein and optionally by action of epothilone modification enzymes and/or by chemically modifying the resulting epothilones produces when those genes are expressed.

Recombinant Methods And Materials For Producing Epothilone And Epothilone Derivatives

View page
US Patent:
6858411, Feb 22, 2005
Filed:
Nov 28, 2000
Appl. No.:
09/724889
Inventors:
Bryan Julien - Oakland CA, US
Leonard Katz - Hayward CA, US
Chaitan Khosla - Palo Alto CA, US
Li Tang - Foster City CA, US
Rainer Ziermann - San Mateo CA, US
Assignee:
Kosan Biosciences, Inc. - Hayward CA
International Classification:
C12P019/62
US Classification:
435 76, 435183, 43525231, 43525233, 536 231, 536 232, 536 237
Abstract:
Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells for the production of epothilones, epothilone derivatives, and polyketides that are useful as cancer chemotherapeutics, fungicides, and immunosuppressants.

Means And Methods For Monitoring Protease Inhibitor Antiretroviral Therapy And Guiding Therapeutic Decisions In The Treatment Of Hiv/Aids

View page
US Patent:
6869759, Mar 22, 2005
Filed:
Jun 12, 2000
Appl. No.:
09/591899
Inventors:
Neil T. Parkin - Belmont CA, US
Rainer A. Ziermann - San Mateo CA, US
Assignee:
ViroLogic, Inc. - South San Francisco CA
International Classification:
C12Q001/70
C12Q011/68
C07H021/04
US Classification:
435 5, 435 6, 536 2372
Abstract:
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.

Recombinant Methods And Materials For Producing Epothilone And Epothilone Derivatives

View page
US Patent:
6921650, Jul 26, 2005
Filed:
Nov 28, 2000
Appl. No.:
09/724876
Inventors:
Bryan Julien - Oakland CA, US
Leonard Katz - Hayward CA, US
Chaitan Khosla - Palo Alto CA, US
Li Tang - Foster City CA, US
Rainer Ziermann - San Mateo CA, US
Assignee:
Kosan Biosciences, Inc. - Hayward CA
International Classification:
C12P019/62
US Classification:
435 76, 536 232, 536 231, 536 237, 43525231, 43525233
Abstract:
Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells for the production of epothilones, epothilone derivatives, and polyketides that are useful as cancer chemotherapeutics, fungicides, and immunosuppressants.

Production Of Polyketides In Bacteria And Yeast

View page
US Patent:
7078233, Jul 18, 2006
Filed:
May 8, 2001
Appl. No.:
09/851650
Inventors:
Philip J. Barr - Oakland CA, US
Daniel V. Santi - San Francisco CA, US
Gary W. Ashley - Alameda CA, US
Rainer Ziermann - San Mateo CA, US
Assignee:
Kosan Biosciences Incorporated - Hayward CA
International Classification:
C12N 5/02
C12N 1/21
C12N 1/19
US Classification:
435410, 43525233, 43525411, 4352542
Abstract:
Hybrid and novel polyketide synthases and polyketides are produced by use of a multiple vector system. The combinatorial possibilities offered by placing the various catalytic activities of PKS systems on separate vectors permits the construction of improved libraries of PKS and polyketides. In addition, polyketides can be produced in hosts that ordinarily do not produce polyketides by supplying, along with an expression system for the desired PKS, an expression system for holo ACP synthase.

Recombinant Methods And Materials For Producing Epothilone And Epothilone Derivatives

View page
US Patent:
7129071, Oct 31, 2006
Filed:
Nov 28, 2000
Appl. No.:
09/724878
Inventors:
Bryan Julien - Oakland CA, US
Leonard Katz - Hayward CA, US
Chaitan Khosla - Palo Alto CA, US
Li Tang - Foster City CA, US
Rainer Ziermann - San Mateo CA, US
Assignee:
KOSAN Biosciences, Inc. - Hayward CA
International Classification:
C12N 9/10
C12N 9/88
C07H 21/04
US Classification:
435193, 435232, 536 232, 536 231, 536 237
Abstract:
Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells for the production of epothilones, epothilone derivatives, and polyketides that are useful as cancer chemotherapeutics, fungicides, and immunosuppressants.

Means And Methods For Monitoring Protease Inhibitor Antiretroviral Therapy And Guiding Therapeutic Decisions In The Treatment Of Hiv/Aids

View page
US Patent:
7138231, Nov 21, 2006
Filed:
Jan 19, 2001
Appl. No.:
09/766344
Inventors:
Neil T. Parkin - Belmont CA, US
Rainer A. Ziermann - San Mateo CA, US
Assignee:
Monogram Biosciences, Inc. - South San Francisco CA
International Classification:
C12Q 1/70
C12P 19/34
C12N 7/00
C12N 15/00
C07H 21/04
US Classification:
435 5, 435 4133, 4352351, 4353201, 536 2372
Abstract:
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.

Means And Methods For Monitoring Protease Inhibitor Antiretroviral Therapy And Guiding Therapeutic Decisions In The Treatment Of Hiv/Aids

View page
US Patent:
7186506, Mar 6, 2007
Filed:
Sep 15, 2000
Appl. No.:
09/663458
Inventors:
Neil T. Parkin - Belmont CA, US
Rainer A. Ziermann - San Mateo CA, US
Assignee:
Monogram Biosciences, Inc. - South San Franisco CA
International Classification:
C12Q 1/68
US Classification:
435 6, 435369, 4353201, 4352351
Abstract:
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.
Rainer A Ziermann from San Diego, CA, age ~61 Get Report